1. Status and future directions of clinical trials in Alzheimer’s disease<br>Germán Plascencia-Villa and George Perry<br>2. Tracking the potential involvement of metabolic disease in Alzheimer's disease—Biomarkers and beyond<br>Jose A. Luchsinger and Henrik Zetterberg<br>3. Brain glucose and ketone utilization in brain aging and neurodegenerative diseases<br>Dimitrios Kapogiannis and Konstantinos I. Avgerinos<br>4. Disturbances in brain energy metabolism in insulin resistance and diabetes and Alzheimer's disease—Learnings from brain imaging biomarkers<br>Kerstin Heurling, Edvin Johansson and Antoine Leuzy<br>5. APOE and metabolic dysfunction in Alzheimer’s disease<br>Lance A. Johnson<br>6. Status and future directions of clinical trials in Parkinson's disease<br>Grażyna Söderbom<br>7. Involvement of GABAergic interneuron dysfunction and neuronal network hyperexcitability in Alzheimer's disease: Amelioration by metabolic switching<br>Mark P. Mattson<br>8. The mitochondrial hypothesis: Dysfunction, bioenergetic defects, and the metabolic link to Alzheimer's disease<br>Russell H. Swerdlow<br>9. MAM and C99, key players in the pathogenesis of Alzheimer’s disease<br>Marta Pera, Jorge Montesinos, Delfina Larrea, Rishi R. Agrawal, Kevin R. Velasco, Irina G. Stavrovskaya, Taekyung D. Yun and Estela Area-Gomez<br>10. Experimental studies of mitochondrial and lysosomal function in in vitro and in vivo models relevant to Parkinson’s disease genetic risk<br>Ria Thomas, Penelope J. Hallett and Ole Isacson<br>11. Endosomal-lysosomal dysfunction in metabolic disorders and Alzheimer's disease<br>Michael F. Almeida, Ben A. Bahr and Stephen T. Kinsey<br>12. Neuroinflammation, microglial activation, and glucose metabolism in neurodegenerative diseases<br>Paul Edison<br>13. The NLRP3 inflammasome as a bridge between neuro-inflammation in metabolic and neurodegenerative diseases<br>Grażyna Söderbom and Bai-Yun Zeng<br>14. Impact of circadian and diurnal rhythms on cellular metabolic function and neurodegenerative diseases<br>S. Kendall Smith and Erik S. Musiek<br>15. The impact of neurovascular, blood-brain barrier, and glymphatic dysfunction in neurodegenerative and metabolic diseases<br>Molly Braun and Jeffrey J. Iliff
